GAMMA Investing LLC Increases Stock Position in Bruker Co. (NASDAQ:BRKR)

GAMMA Investing LLC raised its position in Bruker Co. (NASDAQ:BRKR) by 81.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 867 shares of the medical research company’s stock after buying an additional 388 shares during the period. GAMMA Investing LLC’s holdings in Bruker were worth $60,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Handelsbanken Fonder AB raised its holdings in Bruker by 4.5% in the 3rd quarter. Handelsbanken Fonder AB now owns 368,000 shares of the medical research company’s stock worth $25,414,000 after purchasing an additional 15,800 shares during the period. Centaurus Financial Inc. purchased a new position in shares of Bruker during the 2nd quarter valued at approximately $291,000. Sanctuary Advisors LLC purchased a new stake in Bruker in the 2nd quarter worth $296,000. Gordian Capital Singapore Pte Ltd acquired a new position in Bruker during the second quarter worth $52,000. Finally, Maven Securities LTD lifted its holdings in Bruker by 400.0% during the second quarter. Maven Securities LTD now owns 20,000 shares of the medical research company’s stock valued at $1,276,000 after purchasing an additional 16,000 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Trading Down 2.9 %

NASDAQ BRKR opened at $61.27 on Thursday. Bruker Co. has a one year low of $53.79 and a one year high of $94.86. The firm has a 50 day simple moving average of $65.15 and a 200-day simple moving average of $69.44. The firm has a market cap of $8.90 billion, a price-to-earnings ratio of 22.28, a PEG ratio of 2.52 and a beta of 1.18. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 EPS for the quarter, hitting the consensus estimate of $0.52. The business had revenue of $800.70 million during the quarter, compared to the consensus estimate of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.50 earnings per share. Equities research analysts anticipate that Bruker Co. will post 2.61 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were issued a $0.05 dividend. The ex-dividend date of this dividend was Friday, August 30th. This represents a $0.20 annualized dividend and a yield of 0.33%. Bruker’s dividend payout ratio (DPR) is 7.27%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Bruker in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price target on the stock. Citigroup reduced their price objective on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Wednesday, July 10th. The Goldman Sachs Group dropped their target price on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Finally, Barclays initiated coverage on Bruker in a research report on Tuesday. They set an “overweight” rating and a $75.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $80.82.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.